← All trials
NCT06277050
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 7, 2024
- Primary completion
- Feb 20, 2029
- Completion date
- Feb 20, 2030
- First posted
- Feb 26, 2024
- Last posted
- Apr 30, 2024
- Enrollment
- 264
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangxi Provincial Cancer HospitalLead sponsor
- Jiangxi Provincial Cancer HospitalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.